Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 241-793-5 | CAS number: 17832-28-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Toxicological Summary
- Administrative data
- Workers - Hazard via inhalation route
- Workers - Hazard via dermal route
- Workers - Hazard for the eyes
- Additional information - workers
- General Population - Hazard via inhalation route
- General Population - Hazard via dermal route
- General Population - Hazard via oral route
- General Population - Hazard for the eyes
- Additional information - General Population
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 7.35 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
- Most sensitive endpoint:
- acute toxicity
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Workers - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 2.1 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Modified dose descriptor starting point:
- NOAEL
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
Workers - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- low hazard (no threshold derived)
Additional information - workers
General Remarks
4-(vinyloxy)butan-1-ol (HBVE) is practically exclusively used as an industrial intermediate for the manufacture of vinyl ether polymers and co-polymers. During manufacture and processing of HBVE, worker exposure is controlled by the use of closed systems, industrial hygiene controls, and personal protective equipment. The substance is manufactured and used under strictly controlled conditions over the entire lifecycle. Exposure is limited to occasional sampling tasks for quality control. Transport, storage tanks, reactors, processing equipment, and feeds operate in fully closed systems.
Short term exposure worker (systemic effects)
It is not possible to derive a DNEL for acute effects based on the available data. The acute toxicity of HBVE is low with respect to the inhalative and dermal routes of exposure.
Short term exposure worker (local effects)
HBVE is in accordance with EU Classification, Labelling and Packaging of Substances and Mixtures (CLP) Regulation (EC) No. 1272/2008 classified as eye irritant (cat. 2A). The performed guideline test is not providing dose-response data that could be used for the derivation of a DNEL.
According to the REACH guidance on information requirements and chemical safety assessment, Part E: Risk Characterisation, a qualitative risk characterisation should be performed for this endpoint. In order to guarantee "adequately control of risks", it is necessary to stipulate risk management measures that prevent eye exposure.
Long term exposure worker (systemic effects)
Inhalatory and dermal
The DNELs for inhalatory and dermal long term exposure are derived from the NOAEL obtained in an oral combined repeated dose toxicity study with the reproduction/developmental toxicity screening test (OECD 422; BASF SE 2010). HBVE was administered orally via gavage to groups of 10 male and 10 female Wistar rats (F0 animals) at doses of 50, 150, and 450 mg/kg body weight/day. The duration of treatment covered a 2-week pre-mating and mating period in both sexes, approximately 1 week postmating in males, and the entire gestation period as well as 4 days of lactation in females. No adverse effects on fertility of the F0 parental animals of both sexes at dose levels of 50, 150 and 450 mg/kg bw/d were observed. The test substance caused also no impairments of the reproductive performance. Mating behaviour, conception, gestation, parturition, as well as sexual organ weights and gross and histopathological findings of these organs were not influenced. Slight general systemic toxicity was noted in the F0 parents at 450 mg/kg bw/d. An additional clinical finding was a decreased body weight gain in high-dose males. Concerning clinical pathology no treatment-related, adverse effects were observed up to a dose of 450 mg/kg bw/d. Regarding pathology there were no substance-related organ weight changes, gross lesions, or microscopic findings. Under the conditions of this study the NOAEL for reproductive performance, fertility and for developmental toxicity is 450 mg/kg body weight/day, the highest dose tested. The NOAEL for general, systemic toxicity of the test substance is 150 mg/kg body weight/day for the F0 parental animals based on adverse clinical findings (males + females) and decreased body weight gain (males) at 450 mg/kg body weight/day.
Long term worker (systemic, inhalation)
Description |
Value |
Remark |
Step 1) Relevant dose-descriptor |
NOAEL: 150 mg/kg bw (OECD 422; oral; rat) |
adverse clinical findings and decreased body weight gain |
Step 2) modification of the starting point |
|
|
|
1/0.38 |
route to route (8h exposure) |
|
50/100 |
absorption oral to inhal. |
|
6.7 m³/10 m³ |
to light work |
Step 3) Assessment factors |
|
|
Exposure duration |
6 |
subacute to chronic |
Interspecies |
1 |
no interspecies extrapolation for inhal. |
Intraspecies |
3 |
worker |
DNEL |
Value |
|
For workers |
150 mg/kg x 0.5 x 0.67 / (0.38 x 6 x 1 x 3) = 7.35 mg/m³ |
Long term worker (systemic, dermal)
Description |
Value |
Remark |
Step 1) Relevant dose-descriptor |
NOAEL: 150 mg/kg bw (OECD 422; oral; rat) |
adverse clinical findings and decreased body weight gain |
Step 2) modification of the starting point |
|
|
|
1/1 |
route to route |
Step 3) Assessment factors |
|
|
Exposure duration |
6 |
subacute to chronic |
Interspecies |
4 |
extrapolation systemic effects rat to human |
Intraspecies |
3 |
worker |
DNEL |
Value |
|
For workers |
150 mg/kg / (6 x 4 x 3) = 2.1 mg/kg bw/d |
General Population - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 2.17 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 1.25 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
General Population - Hazard via oral route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 1.25 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
Acute/short term exposure
- Hazard assessment conclusion:
- low hazard (no threshold derived)
- Most sensitive endpoint:
- acute toxicity
DNEL related information
General Population - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- low hazard (no threshold derived)
Additional information - General Population
General Remarks
4-(vinyloxy)butan-1-ol (HBVE) is practically exclusively used as an industrial intermediate for the manufacture of vinyl ether polymers and co-polymers. Consumer exposure to residual HBVE is considered to be negligible, since most of the marketed vinyl ether polymers and co-polymers are heat-treated and potentially existing residual HBVE is expected to evaporate during this process.
Short term exposure general population (systemic effects)
Same considerations as for the worker.
Short term exposure general population (local effects)
Same considerations as for the worker.
Long term exposure general population (systemic effects)
Oral, Inhalatory and dermal
The DNELs for oral, inhalatory and dermal long term exposure are derived from the NOAEL obtained in an oral combined repeated dose toxicity study with the reproduction/developmental toxicity screening test (OECD 422; BASF SE 2010). HBVE was administered orally via gavage to groups of 10 male and 10 female Wistar rats (F0 animals) at doses of 50, 150, and 450 mg/kg body weight/day. The duration of treatment covered a 2-week pre-mating and mating period in both sexes, approximately 1 week postmating in males, and the entire gestation period as well as 4 days of lactation in females. No adverse effects on fertility of the F0 parental animals of both sexes at dose levels of 50, 150 and 450 mg/kg bw/d were observed. The test substance caused also no impairments of the reproductive performance. Mating behaviour, conception, gestation, parturition, as well as sexual organ weights and gross and histopathological findings of these organs were not influenced. Slight general systemic toxicity was noted in the F0 parents at 450 mg/kg bw/d. An additional clinical finding was a decreased body weight gain in high-dose males. Concerning clinical pathology no treatment-related, adverse effects were observed up to a dose of 450 mg/kg bw/d. Regarding pathology there were no substance-related organ weight changes, gross lesions, or microscopic findings. Under the conditions of this study the NOAEL for reproductive performance, fertility and for developmental toxicity is 450 mg/kg body weight/day, the highest dose tested. The NOAEL for general, systemic toxicity of the test substance is 150 mg/kg body weight/day for the F0 parental animals based on adverse clinical findings (males + females) and decreased body weight gain (males) at 450 mg/kg body weight/day.
Long term general population (oral)
Description |
Value |
Remark |
Step 1) Relevant dose-descriptor |
NOAEL: 150 mg/kg bw (OECD 422; oral; rat) |
adverse clinical findings and decreased body weight gain |
Step 2) Assessment factors |
|
|
Exposure duration |
6 |
subacute to chronic |
Interspecies |
4 |
extrapolation systemic effects rat to human |
Intraspecies |
5 |
General population |
DNEL |
Value |
|
For general population |
150 mg/kg / (6 x 4 x 5) = 1.25 mg/kg bw/d |
Long term general population (inhalation)
Description |
Value |
Remark |
Step 1) Relevant dose-descriptor |
NOAEL: 150 mg/kg bw (OECD 422; oral; rat) |
adverse clinical findings and decreased body weight gain |
Step 2) modification of the starting point |
|
|
|
1/1.15 |
route to route (24h exposure) |
|
50/100 |
absorption oral to inhal. |
Step 3) Assessment factors |
|
|
Exposure duration |
6 |
subacute to chronic |
Interspecies |
1 |
no interspecies extrapolation for inhal. |
Intraspecies |
5 |
General population |
DNEL |
Value |
|
For general population |
150 mg/kg x 0.5 / (1.15 x 6 x 1 x 5) = 2.17 mg/m³ |
Long term general population(dermal)
Description |
Value |
Remark |
Step 1) Relevant dose-descriptor |
NOAEL: 150 mg/kg bw (OECD 422; oral; rat) |
adverse clinical findings and decreased body weight gain |
Step 2) modification of the starting point |
|
|
|
1/1 |
route to route |
Step 3) Assessment factors |
|
|
Exposure duration |
6 |
subacute to chronic |
Interspecies |
4 |
extrapolation systemic effects rat to human |
Intraspecies |
5 |
General population |
DNEL |
Value |
|
For general population |
150 mg/kg / (6 x 4 x 5) = 1.25 mg/kg bw/d |
Long term exposure general population (local effects)
Same considerations as for the worker.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.